Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab PK study in Chinese advanced gastric/GEJ cancer
NCT04086758Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from time of dosing extrapolated to time infinity up to 15 months, Percentage of AUCinf up to 15 months and 16 more. Started Oct 2019; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04086758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086758.